Topic
Benzopyran
About: Benzopyran is a research topic. Over the lifetime, 1889 publications have been published within this topic receiving 15235 citations.
Papers published on a yearly basis
Papers
More filters
Patent•
10 Feb 2016
TL;DR: The application of a benzopyran derivative represented as the formula (I) and a pharmaceutically acceptable salt thereof in preparation of drugs for treating hyperuricaemia is discussed in this paper.
Abstract: The invention discloses an application of a benzopyran derivative represented as the formula (I) and a pharmaceutically acceptable salt thereof in preparation of drugs for treating hyperuricaemia. The benzopyran derivative not only has strong in-vitro inhibition effect on xanthine oxidase but also can significantly reduce the serum uric acid level of mice suffered from the hyperuricaemia. The benzopyran derivative has dose-dependent, is free of toxic and side effects, is good in safety and can be used as a potential xanthine oxidase inhibitor and a uric acid reducing medicine for treating the hyperuricaemia and gout or gout complications caused by the hyperuricaemia.
1 citations
Patent•
28 May 2004
TL;DR: In this paper, the use of benzopyran compounds or at least one of them in the preparation of products for preventing or treating hepatitis C was discussed. But this was not the case in this case.
Abstract: The invention relates to the use of benzopyran compounds or at least one of benzopyran compounds in the preparation of products for preventing or treating hepatitis C.
1 citations
Patent•
17 Oct 2003
TL;DR: In this article, the authors provided a preparation process for tetrazole and pharmaceutical compositions containing the same compounds, which compounds do not induce the decrease of blood pressure and inhibit the damage of nervous cells by oxidation stresses.
Abstract: PURPOSE: Benzopyran derivatives substituted with secondary amines including tetrazole, a preparation process thereof and pharmaceutical compositions containing the same compounds are provided, which compounds do not induce the decrease of blood pressure and inhibit the damage of nervous cells by oxidation stresses CONSTITUTION: Benzopyran derivatives substituted with secondary amines including tetrazole represented by the formula 1, stereo isomers thereof or pharmaceutically acceptable salts thereof are provided, wherein R1 is H, F, Cl, Br, CF3, NO2, CN, ORa, OCORa, COORa, NH2, NHS(O)IRa, NHCORa or S(O)IRa; Ra is H, C1-C4 linear or branched chain alkyl or aryl; I is an integer of 0 to 2; R2 is CH2ORa, ORbORc or O(z)O; Rb and Rc are independently C1-C4 linear or branched chain alkyl; Z is C1-C5 linear or branched chain alkyl; R3 is OH, F, Cl, Br, ONO2 or COORa; R4 and R5 are independently H, F, Cl, Br, C1-C3 linear or branched chain alkyl, ORa, CF3, OCF3, NO2, CORa, OCORa, CCOORa or SO3Ra; R6 is hydrogen, C1-C3 linear or branched chain alkyl; n and m are independently an integer of 0 to 2; and * is chiral carbon
1 citations
TL;DR: In this article, the authors proposed three derivatives (IIIa, (IIIe), and (IIIf) for cytotoxicity against different human cancer cell lines, i.e.
Abstract: Derivatives (IIIa), (IIIe), and (IIIf) exhibit promising cytotoxicity against different human cancer cell lines.
1 citations
TL;DR: In this article, Geterotsiklicheskikh Soedinenii, No. 3, pp. 460-461, March, 2006, has translated from Khimiya Geterotikliheskiklikskikh SOedineni, No., 3, 2006.
Abstract: __________ Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 3, pp. 460–461, March, 2006.
1 citations